HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US TELL FRIEND RSS
 
Welcome to FDAweb
Pay Per View
Search our 59,299 - story database FREE
 
Free Items
 Warning Letters
 FDA Notices
 FDA Calendar
 

 FDA Whistleblowers



    








 
 
<< Prev  13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Next >>
 
TXT FDA Warns on Burkholderia Cepacia Contamination [216 Words] [ Price : $8.95]
FDA warns drug manufacturers of non-sterile, water-based drug products that there have been the subject of recent product recalls due to Burkholderia cepacia complex contamination.
05/22/2017
 
 
TXT FDA OKs Rocheís Actemra for Giant Cell Arteritis [236 Words] [ Price : $8.95]
FDA expands the approved use of Hoffman La Rocheís subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis.
05/22/2017
 
 
TXT Celgene Reports Positive Data in Multiple Sclerosis Trial [117 Words] [ Price : $8.95]
Celgene says its Phase 3 RADIANCE trial met its primary endpoint in evaluating the efficacy and safety of ozanimod in patients with relapsing multiple sclerosis.
05/22/2017
 
 
TXT No Risks Cited in Gadolinium-based Product Review: FDA [291 Words] [ Price : $8.95]
An ongoing FDA review of the risk of brain deposits following repeated use of gadolinium-based contrast agents for MRIs identifies no adverse health effects.
05/22/2017
 
 
TXT Respironics Class 1 Recall of Ventilators [149 Words] [ Price : $8.95]
Respironics begins a Class 1 recall of its V60 Non-invasive Ventilator because the pins within the internal cable that connects the ventilator's motor to the control board may become loose over time and shut the device down.
05/22/2017
 
 
TXT Soterix Medical Iontophoresis Device Cleared [128 Words] [ Price : $8.95]
FDA clears a Soterix Medical 510(k) for its IontoDC device, which uses a direct current to introduce ions of soluble salts or other drugs into the body.
05/22/2017
 
 
TXT Celgene Reports Positive Data in Multiple Sclerosis Trial [117 Words] [ Price : $8.95]
Celgene says its Phase 3 RADIANCE trial met its primary endpoint in evaluating the efficacy and safety of ozanimod in patients with relapsing multiple sclerosis.
05/22/2017
 
 
TXT FDA Releases Sancilio, FL Form 483 [114 Words] [ Price : $8.95]
FDA releases a Form 483 after a January inspection cited significant GMP issues at Sancilio & Co.ís Riviera Beach, FL manufacturing facility.
05/22/2017
 
 
TXT FDA Releases Sekisui Medical FDA-483 [2726 Words] [ Price : $8.95]
FDA releases the FDA-483 issued following a 2016 inspection at Japanís Sekisui Medical API manufacturer.
05/19/2017
 
 
TXT Eyes on Gottlieb as He Heads for First Hill Testimony [252 Words] [ Price : $8.95]
Newly sworn-in FDA commissioner Scott Gottlieb visits Capitol Hill for his first testimony as the agency head 5/25 during a House budget hearing.
05/19/2017
 
 
<< Prev  13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  Next >>
 

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com